BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105 [PMID: 28439491 DOI: 10.5306/wjco.v8.i2.100]
URL: https://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
Number Citing Articles
Soichi Matsumura, Taigo Kato, Yuma Kujime, Hiroaki Kitakaze, Kosuke Nakano, Sachiko Hongo, Iwao Yoshioka, Masayoshi Okumi, Norio Nonomura, Shingo Takada. Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumabBMC Urology 2023; 23(1) doi: 10.1186/s12894-023-01248-z
Veronica Mollica, Matteo Rosellini, Stefano Brocchi, Francesco Galuppi, Alexandro Paccapelo, Valentina Tateo, Andrea Marchetti, Elisa Tassinari, Francesco Mantuano, Matteo Santoni, Francesco Massari. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinomaExpert Review of Precision Medicine and Drug Development 2024; 9(1): 17 doi: 10.1080/23808993.2024.2330422
Candice Schwartz, Nicklas Pfanzelter, Timothy M. Kuzel. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non–Clear-Cell Renal Cell Carcinoma: A Case Report and Literature ReviewClinical Genitourinary Cancer 2017; 15(5): e903 doi: 10.1016/j.clgc.2017.05.017
Guobin Chen, Xiaoying Xie, Meixia Wang, Xinkun Guo, Zhenzhen Zhang, Lan Zhang, Boheng Zhang. Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial ChemoembolizationCurrent Oncology 2022; 29(2): 423 doi: 10.3390/curroncol29020038
Marwan Ghosn, Joseph Kattan, Fadi El Karak, Hady Ghanem, Jamil Debs, Khaled Ibrahim, Ali Shamseddine. Renal cell carcinoma management: real-world practice and challenges at a national levelFuture Oncology 2023; 19(12): 863 doi: 10.2217/fon-2021-1189
Pawel Chrom, Maciej Kawecki, Rafal Stec, Lubomir Bodnar, Cezary Szczylik, Anna M. Czarnecka. Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinomaMedical Oncology 2018; 35(6) doi: 10.1007/s12032-018-1148-x
Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno J.E.M.A. Debets, Egbert F. Smit, Joachim G.J.V. Aerts. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysisERJ Open Research 2019; 5(4): 00179-2019 doi: 10.1183/23120541.00179-2019
Melissa Bersanelli, Sebastiano Buti. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potentialTherapeutic Advances in Medical Oncology 2017; 9(10): 627 doi: 10.1177/1758834017724314
Ehab Abdou, Ravi M. Pedapenki, Mohamed Abouagour, Abdul R. Zar, Emad Dawoud, Dalia Elshourbagy, Humaid O. Al-Shamsi, Enrique Grande. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinomaExpert Review of Anticancer Therapy 2020; 20(10): 831 doi: 10.1080/14737140.2020.1810572
Li-na He, Xuanye Zhang, Haifeng Li, Tao Chen, Chen Chen, Yixin Zhou, Zuan Lin, Wei Du, Wenfeng Fang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 TherapyFrontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.621329
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET studyJournal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
Anna M. Czarnecka, Anna Brodziak, Pawel Sobczuk, Cezary Dendek, Dominika Labochka, Jan Korniluk, Ewa Bartnik, Cezary Szczylik. Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell CarcinomaScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-44226-y